Suppression of hepatocellular carcinoma recurrence after rat liver transplantation by FTY720, a sphingosine-1-phosphate analog

Transplantation

Volumn 88, Issue 8, 2009, Pages 980-986

  Ushitora, Yuichiro ^a   Tashiro, Hirotaka ^a   Ogawa, Takayuki ^a   Tanimoto, Yoshisato ^a   Kuroda, Shintaro ^a   Kobayashi, Tsuyoshi ^a   Miyata, Yoshihiro ^a   Itamoto, Toshiyuki ^a   Asahara, Toshimasa ^a   Ohdan, Hideki ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

FTY720; Hepatocellular carcinoma; Liver transplantation; Recurrence.; Sphingosine 1 phosphate

Indexed keywords

FINGOLIMOD; MITOGEN ACTIVATED PROTEIN KINASE; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER INVASION; CANCER RECURRENCE; CARCINOMA CELL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; LIVER CARCINOMA; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; RECURRENT CANCER; SURVIVAL TIME;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; CULTURE MEDIA; DOWN-REGULATION; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PROPYLENE GLYCOLS; RATS; RATS, INBRED BUF; RECEPTORS, LYSOSPHINGOLIPID; RECURRENCE; SPHINGOSINE;

EID: 70350444557     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181b9ca69     Document Type: Article

References (34)

1. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment ofsmall hepatocellular carcinomasinpatients with cirrhosis. N Engl J Med 1996; 334: 693.
2. Vivarelli M, Bellusci R, Cucchetti A, et al. Low recurrence rate of hep-atocellular carcinoma after liver transplantation: Better patient selection or lower immunosuppression? Transplantation 2002; 74: 1746.
3. Toso C, Meeberg GA, Bigam DL, et al. De novo sirolimus-based im-munosuppression after liver transplantation for hepatocellular carcinoma: Long-term outcomes and side effects. Transplantation 2007; 83: 1162.
4. Olivera A, Spiegel S. Sphingosine-1-phosphate as a second messenger in cell proliferation induced by PDGF and FCS mitogens. Nature 1993; 365: 557.
5. Hannum YA, Obeid LM. Principles ofbioactive lipid signaling: Lessons from sphingolipids. Nat Rev Mol Cell Biol 2008; 9: 139.
6. SpiegelS,MilstienS. Sphingosine-1-phosphate:Anenigmatic signaling lipid. Nat Rev Mol Cell Biol 2003; 4: 397.
7. Lee MJ, Brocklyn JRV, Thangada S, et al. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science 1998; 278: 1552.
8. Hla T, Lee M, Ancellin N, et al. Lysophospholipids-receptor revelations. Science 2001; 294: 1875.
9. Spiegel S, Milstein S. Sphingosine-1-phosphte: Signaling inside and out. FEBS Lett 2000; 476: 55.
10. Okamoto H,TakuwaN,YokomizoT,etal. Inhibitory regulationof Rac activation, membrane ruffling, and cell migration by the G protein-coupled shingpsine-1-phosphate receptor EDG5 but not EDG1 or EDG3. Mol Cell Biol 2000; 20: 9247.
11. Zhou C, Ling MT, Lee TKW, et al. FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase. Cancer Lett 2006; 233: 36.
12. Lepley D, Paik JH, Hla T, et al. The G protein-coupled receptor S1P2 regulates Rho/Rho kinase pathway to inhibit tumor cell migration. Cancer Res 2005; 65: 3788.
13. Malchinkhuu E,Sato K, Horiuchi Y, etal. Roleofp38 mitogen-acivated kinase and c-Jun terminal kinase in migration response to lysophos-phatidic acid and sphingosine-1-phosphate in glioma cells. Oncogene 2005; 24: 6676.
14. Julien D, Li L, Mallat A, et al. Shingosine-1-phosphate triggers both apoptotic and survival signals for human hepatic myofibroblasts. J Biol Chem 2002; 277: 37323.
15. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296: 346.
16. Matloublan M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427: 355.
17. LaMontagne K, Littlewood-Evans A, Schnell C, et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 2006; 66: 221.
18. Lee TK, Man K, Ho JW, et al. Significance of the Rac signaling pathway in HCC cell motility: Implications for a new therapeutic target. Carci-nogenesis 2005; 26: 681.
19. Schmid G, Guba M, Ischenko I, et al. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine-1-phosphate receptor 1. J Cell Biochem 2007; 101: 259.
20. Yang R, Rescorla FJ, Reilly CR, et al. A reproducible rat liver cancer model for experimental therapy: Introducing a technique of intrahe-patic tumor implantation. J Surg Res 1992; 52: 193.
21. Tashiro H, Fudaba Y, Itoh H, et al. Hepatocyte growth factor prevents chronic allograft dysfunction in liver-transplanted rats. Transplantation 2003; 76: 761.
22. Takuwa Y. Subtype-specific differential regulation of Rho family G proteins and cell migration by the edg family sphigosine-1-phosphate receptors. Biochim Biophys Acta 2002; 1582: 112.
23. Yamauchi H, Kitayama J, Takuwa N, et al. Sphingosine-1-phosphate receptor subtype-specific positive and negative regulation of Rac and haematogenous metastasis of melanoma cells. Biochem J 2003; 374: 715.
24. Dolezalova H, Shankar G, Huang MC, et al. Biochemical regulation of breast cancer cell expression of S1P2 (Edg-5) and S1P3 (Edg-3) G protein-coupled receptors for sphingosine 1-phosphate. J Cell Biochem 2003; 88: 732.
25. Yamashita H, Kitayama J, Shida D, et al. Sphingosine 1-phosphate receptor expression profile in human gastric cancer cells: Differential regulation on the migration and proliferation. J Surg Res 2006; 130:80.
26. Gonzalez-Cabrera P, Hla T, Rosen H. Mapping pathways downstream of sphingosine 1-phosphate subtype 1 by differential chemical perturbation. J Biol Chem 2007; 282: 7254.
27. Oo ML, Thangada S, Wu MT, et al. Immunosuppressive and antiangiogeneic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem 2007; 282:9082.
28. Okamoto H, Takuwa N, Yatomi Y, et al. EDG3 is a functional receptor specific for sphingosine 1-phosphate and sphingosylphosphorylcho-line with signaling characteristics distinct from EDG1 and AGR16. Biochem Biophys Res Commun 1999; 260: 203.
29. Visentin B, Vekich JA, Sibbald BJ, et al. Validation of an anti-sphingosine-1-phospahate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 2006; 9: 225.
30. Lee TK, Man K, Ho JW, et al. FTY720: A promising agent for treatment of metastatic hepatocellular carcinoma. Clin Cancer Res 2005; 11:8458.
31. Hung JH, Lu YS, Wang YC, et al. FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C 8 signaling. Cancer Res 2008; 68: 1204.
32. Salvadori M, Budde K, Charpentier B, et al.; for the FTY720 0124 study group. FTY720 versus MMF with cyclosporine in de novo renal transplantation: A 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant 2006; 7: 2912.
33. Zhang Z, Zhang ZY, Fauser U, et al. FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves. Exp Neurol 2008; 210: 681.
34. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355: 1124.